Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hillary Haws"'
Autor:
Katherine K. Soh, Peter Peterson, Clifford J. Whatcott, Ye Sol Lee, Hillary Haws, Keith Stewart, Devora Delman, Chang Xin Shi, Steven L. Warner, Adam Siddiqui-Jain, James M Bogenberger, Nanna Hansen, Raoul Tibes, Wontak Kim, Steven D. Weitman, David J. Bearss, Ruben A. Mesa
Publikováno v:
Oncotarget
More effective treatment options for elderly acute myeloid leukemia (AML) patients are needed as only 25-50% of patients respond to standard-of-care therapies, response duration is typically short, and disease progression is inevitable even with some
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87e135cb838c70e8087b3be8a784d39e
https://pubmed.ncbi.nlm.nih.gov/29291023
https://pubmed.ncbi.nlm.nih.gov/29291023
Autor:
Clifford J. Whatcott, Adam Siddiqui-Jain, David J. Bearss, Steven L. Warner, Raoul Tibes, James L. Bogenberger, Hubert F. Arokium, Hillary Haws
Publikováno v:
Cancer Research. 78:883-883
The positive-transcription elongation factor (P-TEFb) complex is critical in stimulating the transcription of non-abortive transcripts by RNA polymerase II. The CDK9/cyclin-T heterodimer comprises the P-TEFb complex and promotes transcription elongat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de395a4bdf68dc5fe2894a3d3a0e7ec9
https://doi.org/10.1158/1538-7445.am2018-883
https://doi.org/10.1158/1538-7445.am2018-883
Autor:
Hillary Haws, Peter Peterson, Steven L. Warner, Adam Siddiqui-Jain, Steven D. Weitman, David J. Bearss, Clifford J. Whatcott, Wontak Kim
Publikováno v:
Cancer Research. 77:5133-5133
Alvocidib is a potent inhibitor of cyclin-dependent kinase-9 (CDK9) and induces apoptosis in cancer cells by reducing the expression of short-lived, anti-apoptotic proteins such as MCL-1. Alvocidib, as a part of a sequential combination regimen with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f51bec7f292b642cecb5bd00e3c2bfb
https://doi.org/10.1158/1538-7445.am2017-5133
https://doi.org/10.1158/1538-7445.am2017-5133
Autor:
Clifford J. Whatcott, Steven L. Warner, Adam Siddiqui-Jain, Steven D. Weitman, David J. Bearss, Wontak Kim, Hillary Haws, Peter Peterson, Mark Livingston
Publikováno v:
Cancer Research. 77:1106-1106
The proteasome inhibitor bortezomib is widely used in the treatment of patients with multiple myeloma (MM). The expression levels of many proteins increase as a result of bortezomib treatment, including the pro-apoptotic protein NOXA. NOXA functions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5eccf9bd0270595b6f315a837fc455f
https://doi.org/10.1158/1538-7445.am2017-1106
https://doi.org/10.1158/1538-7445.am2017-1106
Autor:
James M Bogenberger, Raoul Tibes, Peter Peterson, Clifford J. Whatcott, Lisa Sproat, Adam Siddiqui-Jain, Devora Delman, Wontak Kim, Steven L. Warner, Nanna Hansen, Hillary Haws, Ruben A. Mesa, Steven D. Weitman, David J. Bearss, Jeanne Palmer
Publikováno v:
Blood. 128:1652-1652
Introduction Venetoclax (ABT-199) is an approved BCL-2 inhibitor for the treatment of patients with chronic lymphocytic leukemia (CLL). Multiple clinical trials are underway to explore its efficacy in additional indications. While venetoclax demonstr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdde075d36461e5048bc6768d2f5f714
https://doi.org/10.1182/blood.v128.22.1652.1652
https://doi.org/10.1182/blood.v128.22.1652.1652
Autor:
Peter Peterson, Hillary Haws, Steven L. Warner, Clifford J. Whatcott, David J. Bearss, Adam Siddiqui-Jain, Wontak Kim
Publikováno v:
Blood. 128:263-263
In individuals with chronic inflammatory diseases, such as cancer or rheumatoid arthritis, constitutive signaling through ALK2, a member of the bone morphogenetic protein (TGFβ/BMP) receptor family, leads to debilitating anemia, commonly referred to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a93b36bf5c77380c0d93654f7a02a480
https://doi.org/10.1182/blood.v128.22.263.263
https://doi.org/10.1182/blood.v128.22.263.263